EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma
On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended adding a new indication for isatuximab, a monoclonal antibody treatment marketed by Sanofi as Sarclisa ®. The CHMP is the European…